Global Diltiazem Hydrochloride Injection 麻豆原创 Research Report 2025

Publication ID:

PB502253223

Publication Date:

February 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Diltiazem Hydrochloride Injection was valued at US$ 631 million in the year 2024 and is projected to reach a revised size of US$ 853 million by 2031, growing at a CAGR of 4.4% during the forecast period.
Diltiazem Hydrochloride Injection is a calcium channel blocker (CCB) used primarily for cardiac arrhythmias, hypertension, and angina. It works by blocking calcium influx into cardiac and vascular smooth muscle cells, leading to reduced heart rate, lower blood pressure, and improved blood flow.
North American market for Diltiazem Hydrochloride Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Diltiazem Hydrochloride Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Diltiazem Hydrochloride Injection include Pfizer, AdvaCare Pharma, Mylan Pharmaceuticals, Eugia US, SagentPharma, Torrent Pharmaceuticals, Hikma Pharmaceuticals, Nova Plus Pharmaceuticals, SGPharma, SHANDONG FANGMING BANGJIA PHARMACEUTICAL, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Diltiazem Hydrochloride Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diltiazem Hydrochloride Injection.
The Diltiazem Hydrochloride Injection market size, estimations, and forecasts are provided in terms of sales volume (L) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Diltiazem Hydrochloride Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diltiazem Hydrochloride Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Pfizer
AdvaCare Pharma
Mylan Pharmaceuticals
Eugia US
SagentPharma
Torrent Pharmaceuticals
Hikma Pharmaceuticals
Nova Plus Pharmaceuticals
SGPharma
SHANDONG FANGMING BANGJIA PHARMACEUTICAL
JiangSu WuZhong Pharmaceutical
Zhejiang Yatai Pharmaceutical
Shanghai Pharmaceuticals
Segment by Type
10mg/1ml
10mg/2ml
Segment by Application
Cardiovascular System Diseases
Surgery-Related Applications
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Diltiazem Hydrochloride Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Diltiazem Hydrochloride Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Diltiazem Hydrochloride Injection 麻豆原创 Overview
1.1 Product Definition
1.2 Diltiazem Hydrochloride Injection by Type
1.2.1 Global Diltiazem Hydrochloride Injection 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 10mg/1ml
1.2.3 10mg/2ml
1.3 Diltiazem Hydrochloride Injection by Application
1.3.1 Global Diltiazem Hydrochloride Injection 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Cardiovascular System Diseases
1.3.3 Surgery-Related Applications
1.4 Global Diltiazem Hydrochloride Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Diltiazem Hydrochloride Injection Revenue 2020-2031
1.4.2 Global Diltiazem Hydrochloride Injection Sales 2020-2031
1.4.3 Global Diltiazem Hydrochloride Injection 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Diltiazem Hydrochloride Injection 麻豆原创 Competition by Manufacturers
2.1 Global Diltiazem Hydrochloride Injection Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Diltiazem Hydrochloride Injection Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Diltiazem Hydrochloride Injection Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Diltiazem Hydrochloride Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Diltiazem Hydrochloride Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Diltiazem Hydrochloride Injection, Product Type & Application
2.7 Global Key Manufacturers of Diltiazem Hydrochloride Injection, Date of Enter into This Industry
2.8 Global Diltiazem Hydrochloride Injection 麻豆原创 Competitive Situation and Trends
2.8.1 Global Diltiazem Hydrochloride Injection 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Diltiazem Hydrochloride Injection Players 麻豆原创 Share by Revenue
2.8.3 Global Diltiazem Hydrochloride Injection Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Diltiazem Hydrochloride Injection 麻豆原创 Scenario by Region
3.1 Global Diltiazem Hydrochloride Injection 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Diltiazem Hydrochloride Injection Sales by Region: 2020-2031
3.2.1 Global Diltiazem Hydrochloride Injection Sales by Region: 2020-2025
3.2.2 Global Diltiazem Hydrochloride Injection Sales by Region: 2026-2031
3.3 Global Diltiazem Hydrochloride Injection Revenue by Region: 2020-2031
3.3.1 Global Diltiazem Hydrochloride Injection Revenue by Region: 2020-2025
3.3.2 Global Diltiazem Hydrochloride Injection Revenue by Region: 2026-2031
3.4 North America Diltiazem Hydrochloride Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America Diltiazem Hydrochloride Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Diltiazem Hydrochloride Injection Sales by Country (2020-2031)
3.4.3 North America Diltiazem Hydrochloride Injection Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Diltiazem Hydrochloride Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe Diltiazem Hydrochloride Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Diltiazem Hydrochloride Injection Sales by Country (2020-2031)
3.5.3 Europe Diltiazem Hydrochloride Injection Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Diltiazem Hydrochloride Injection 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Diltiazem Hydrochloride Injection 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Diltiazem Hydrochloride Injection Sales by Region (2020-2031)
3.6.3 Asia Pacific Diltiazem Hydrochloride Injection Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Diltiazem Hydrochloride Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Diltiazem Hydrochloride Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Diltiazem Hydrochloride Injection Sales by Country (2020-2031)
3.7.3 Latin America Diltiazem Hydrochloride Injection Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Diltiazem Hydrochloride Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Diltiazem Hydrochloride Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Diltiazem Hydrochloride Injection Sales by Country (2020-2031)
3.8.3 Middle East and Africa Diltiazem Hydrochloride Injection Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Diltiazem Hydrochloride Injection Sales by Type (2020-2031)
4.1.1 Global Diltiazem Hydrochloride Injection Sales by Type (2020-2025)
4.1.2 Global Diltiazem Hydrochloride Injection Sales by Type (2026-2031)
4.1.3 Global Diltiazem Hydrochloride Injection Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Diltiazem Hydrochloride Injection Revenue by Type (2020-2031)
4.2.1 Global Diltiazem Hydrochloride Injection Revenue by Type (2020-2025)
4.2.2 Global Diltiazem Hydrochloride Injection Revenue by Type (2026-2031)
4.2.3 Global Diltiazem Hydrochloride Injection Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Diltiazem Hydrochloride Injection Price by Type (2020-2031)
5 Segment by Application
5.1 Global Diltiazem Hydrochloride Injection Sales by Application (2020-2031)
5.1.1 Global Diltiazem Hydrochloride Injection Sales by Application (2020-2025)
5.1.2 Global Diltiazem Hydrochloride Injection Sales by Application (2026-2031)
5.1.3 Global Diltiazem Hydrochloride Injection Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Diltiazem Hydrochloride Injection Revenue by Application (2020-2031)
5.2.1 Global Diltiazem Hydrochloride Injection Revenue by Application (2020-2025)
5.2.2 Global Diltiazem Hydrochloride Injection Revenue by Application (2026-2031)
5.2.3 Global Diltiazem Hydrochloride Injection Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Diltiazem Hydrochloride Injection Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Diltiazem Hydrochloride Injection Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AdvaCare Pharma
6.2.1 AdvaCare Pharma Company Information
6.2.2 AdvaCare Pharma Description and Business Overview
6.2.3 AdvaCare Pharma Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AdvaCare Pharma Diltiazem Hydrochloride Injection Product Portfolio
6.2.5 AdvaCare Pharma Recent Developments/Updates
6.3 Mylan Pharmaceuticals
6.3.1 Mylan Pharmaceuticals Company Information
6.3.2 Mylan Pharmaceuticals Description and Business Overview
6.3.3 Mylan Pharmaceuticals Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Mylan Pharmaceuticals Diltiazem Hydrochloride Injection Product Portfolio
6.3.5 Mylan Pharmaceuticals Recent Developments/Updates
6.4 Eugia US
6.4.1 Eugia US Company Information
6.4.2 Eugia US Description and Business Overview
6.4.3 Eugia US Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Eugia US Diltiazem Hydrochloride Injection Product Portfolio
6.4.5 Eugia US Recent Developments/Updates
6.5 SagentPharma
6.5.1 SagentPharma Company Information
6.5.2 SagentPharma Description and Business Overview
6.5.3 SagentPharma Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.5.4 SagentPharma Diltiazem Hydrochloride Injection Product Portfolio
6.5.5 SagentPharma Recent Developments/Updates
6.6 Torrent Pharmaceuticals
6.6.1 Torrent Pharmaceuticals Company Information
6.6.2 Torrent Pharmaceuticals Description and Business Overview
6.6.3 Torrent Pharmaceuticals Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Torrent Pharmaceuticals Diltiazem Hydrochloride Injection Product Portfolio
6.6.5 Torrent Pharmaceuticals Recent Developments/Updates
6.7 Hikma Pharmaceuticals
6.7.1 Hikma Pharmaceuticals Company Information
6.7.2 Hikma Pharmaceuticals Description and Business Overview
6.7.3 Hikma Pharmaceuticals Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Hikma Pharmaceuticals Diltiazem Hydrochloride Injection Product Portfolio
6.7.5 Hikma Pharmaceuticals Recent Developments/Updates
6.8 Nova Plus Pharmaceuticals
6.8.1 Nova Plus Pharmaceuticals Company Information
6.8.2 Nova Plus Pharmaceuticals Description and Business Overview
6.8.3 Nova Plus Pharmaceuticals Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Nova Plus Pharmaceuticals Diltiazem Hydrochloride Injection Product Portfolio
6.8.5 Nova Plus Pharmaceuticals Recent Developments/Updates
6.9 SGPharma
6.9.1 SGPharma Company Information
6.9.2 SGPharma Description and Business Overview
6.9.3 SGPharma Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.9.4 SGPharma Diltiazem Hydrochloride Injection Product Portfolio
6.9.5 SGPharma Recent Developments/Updates
6.10 SHANDONG FANGMING BANGJIA PHARMACEUTICAL
6.10.1 SHANDONG FANGMING BANGJIA PHARMACEUTICAL Company Information
6.10.2 SHANDONG FANGMING BANGJIA PHARMACEUTICAL Description and Business Overview
6.10.3 SHANDONG FANGMING BANGJIA PHARMACEUTICAL Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.10.4 SHANDONG FANGMING BANGJIA PHARMACEUTICAL Diltiazem Hydrochloride Injection Product Portfolio
6.10.5 SHANDONG FANGMING BANGJIA PHARMACEUTICAL Recent Developments/Updates
6.11 JiangSu WuZhong Pharmaceutical
6.11.1 JiangSu WuZhong Pharmaceutical Company Information
6.11.2 JiangSu WuZhong Pharmaceutical Description and Business Overview
6.11.3 JiangSu WuZhong Pharmaceutical Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.11.4 JiangSu WuZhong Pharmaceutical Diltiazem Hydrochloride Injection Product Portfolio
6.11.5 JiangSu WuZhong Pharmaceutical Recent Developments/Updates
6.12 Zhejiang Yatai Pharmaceutical
6.12.1 Zhejiang Yatai Pharmaceutical Company Information
6.12.2 Zhejiang Yatai Pharmaceutical Description and Business Overview
6.12.3 Zhejiang Yatai Pharmaceutical Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Zhejiang Yatai Pharmaceutical Diltiazem Hydrochloride Injection Product Portfolio
6.12.5 Zhejiang Yatai Pharmaceutical Recent Developments/Updates
6.13 Shanghai Pharmaceuticals
6.13.1 Shanghai Pharmaceuticals Company Information
6.13.2 Shanghai Pharmaceuticals Description and Business Overview
6.13.3 Shanghai Pharmaceuticals Diltiazem Hydrochloride Injection Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Shanghai Pharmaceuticals Diltiazem Hydrochloride Injection Product Portfolio
6.13.5 Shanghai Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Diltiazem Hydrochloride Injection Industry Chain Analysis
7.2 Diltiazem Hydrochloride Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Diltiazem Hydrochloride Injection Production Mode & Process Analysis
7.4 Diltiazem Hydrochloride Injection Sales and 麻豆原创ing
7.4.1 Diltiazem Hydrochloride Injection Sales Channels
7.4.2 Diltiazem Hydrochloride Injection Distributors
7.5 Diltiazem Hydrochloride Injection Customer Analysis
8 Diltiazem Hydrochloride Injection 麻豆原创 Dynamics
8.1 Diltiazem Hydrochloride Injection Industry Trends
8.2 Diltiazem Hydrochloride Injection 麻豆原创 Drivers
8.3 Diltiazem Hydrochloride Injection 麻豆原创 Challenges
8.4 Diltiazem Hydrochloride Injection 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
AdvaCare Pharma
Mylan Pharmaceuticals
Eugia US
SagentPharma
Torrent Pharmaceuticals
Hikma Pharmaceuticals
Nova Plus Pharmaceuticals
SGPharma
SHANDONG FANGMING BANGJIA PHARMACEUTICAL
JiangSu WuZhong Pharmaceutical
Zhejiang Yatai Pharmaceutical
Shanghai Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.